Lars Ekman
InvestorExecutive Partner, Private Equity at Sofinnova Ventures
San Diego, California
Writes $100K – $5M checks · typically $1.5M
About
Lars Ekman is a global R&D executive and drug developer with more than 30 years of experience across executive, scientific, and clinical roles, and he brings his life science background to the investment team. Before joining Sofinnova in 2008, he was President of Research and Development at Elan, having earlier held R&D leadership at Schwarz Pharma AG and various senior scientific and clinical roles at Pharmacia (now Pfizer). He earned his MD and PhD from the University of Gothenburg, Sweden, and is a board-certified surgeon with a PhD in Experimental Biology.
Invests in
Biotech
Experience
- Sofinnova VenturesExcecutive Partnercurrent2007 — presentLa Jolla - San Diego, Menlo Park, CA
- Elan PharmaceuticalsEVP, President of Research & Development2001 — 2007San Diego, San Francisco, New York, Dublin
- Schwarz PharmaPresident R&D1996 — 2001Greater Dusseldorf Area
- Pharmacia GmbHEVP, Research and Development1989 — 1996Erlangen, Bavaria, Germany
- Pharmacia ABVice President of Research and Development1983 — 1989Greater Stockholm Metropolitan Area
Education
- University of GothenburgMD, PhD, Medicine and Molecular Biology1968 — 1974
Skills & more
+8 more
CommercializationMedical DevicesClinical DevelopmentCorporate DevelopmentDrug DiscoveryClinical TrialsOncologyRegulatory Affairs- Board Certified Surgeon — The Swedish Medical Association
From Lars's professional profile.
Same school
Also attended University of Gothenburg43
+ 37 more
Shared employers
Also worked at Elan Pharmaceuticals2
Deals · 1
Aeovian PharmaceuticalsBoard seat
via Sofinnova Ventures · filed Dec 2025 · $55M raise
Attribution from SEC filings, press coverage, and firm rosters.
